TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3110248

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP), 200 micrograms twice daily
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sodium cromoglycate (SCG), 2 mg four times daily
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both treatments (BDP and SCG)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sodium cromoglycate (SCG) in the second period
Number of subjects: 38
Study: 29880873

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 29
Study: 27242121

Group type: EXPERIMENTAL
Intervention: 30mg zinc sulphate dispersible tablet, once daily for six months
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo, once daily for six months
Number of subjects: 55
Study: 23582750

Group type: EXPERIMENTAL
Intervention: Mahjong
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control (simple handicrafts)
Number of subjects: 110
Study: 22958612

Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D levels in overweight/obese individuals
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D levels in individuals with metabolic syndrome
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D levels
Number of subjects: 601
Study: 20592230

Group type: EXPERIMENTAL
Intervention: Habitual lens wear
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: PHMB-preserved solution
Number of subjects: 48

Group type: COMPARATOR
Intervention: Polyquad/Aldox system
Number of subjects: 48
Study: 16644196

Group type: EXPERIMENTAL
Intervention: Hochu-ekki-to (HET) 7.5 g/day for two weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (indistinguishable) 7.5 g/day for two weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: HET and Control (Placebo)
Number of subjects: 32
Study: 16249679

Group type: EXPERIMENTAL
Intervention: Combined spinal‐epidural technique with 27‐gauge Whitacre needle dural puncture without subarachnoid drug administration
Number of subjects: 251

Group type: COMPARATOR
Intervention: Traditional epidural technique
Number of subjects: 251
Study: 11867391

Group type: COMPARATOR
Intervention: Propofol anesthesia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 30
Study: 10667430

Group type: EXPERIMENTAL
Intervention: 3 months combined androgen blockade therapy (n = 18)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 6 months combined androgen blockade therapy (n = 22)
Number of subjects: 40
Study: 8675576

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1858189

Group type: EXPERIMENTAL
Intervention: Indomethacin 100 mg administered as an enema
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 6136287

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Gallamine
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Tubocurarine
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 198

Group type: COMPARATOR
Intervention: Inert medication (Control)
Number of subjects: 198
Study: 31264430

Group type: EXPERIMENTAL
Intervention: 70-gene MammaPrint assay
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 28346843

Group type: EXPERIMENTAL
Intervention: Maternal milk odor during venipuncture
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (odorless diffuser)
Number of subjects: 33
Study: 27986742

Group type: EXPERIMENTAL
Intervention: Ethosuximide for 6 weeks
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control treatment for 6 weeks
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Ethosuximide
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 220
Study: 23755902

Group type: EXPERIMENTAL
Intervention: Removable partial dentures (RPDs) constructed from Co‐Cr‐Mo alloy
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Removable partial dentures (RPDs) constructed from Ti6Al4V alloy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Buffered saline solution (in vitro)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Saliva samples (in vivo)
Number of subjects: 28
Study: 22370326

Group type: EXPERIMENTAL
Intervention: Doxorubicin alone
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Doxorubicin with dexrazoxane
Number of subjects: 205
Study: 19574864

Group type: EXPERIMENTAL
Intervention: Paravertebral block (PVB) of 2 segments at T10 and L1 vertebrae levels
Number of subjects: 50

Group type: COMPARATOR
Intervention: Paravertebral block (PVB) through 4 segments at T10, T11, T12, and L1
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Propofol and remifentanil consumption
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Surgery start time
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Postoperative visual analog scale scores
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Complications
Number of subjects: 50
Study: 17878242

Group type: EXPERIMENTAL
Intervention: Vildagliptin monotherapy (100 mg daily)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Active comparator group
Number of subjects: 238
Study: 14763497

Group type: EXPERIMENTAL
Intervention: Dialyzer reprocessing
Number of subjects: 1285

Group type: EXPERIMENTAL
Intervention: Qb above 250 ml/min
Number of subjects: 1285

Group type: EXPERIMENTAL
Intervention: Increased Qd from 500 to 800 ml/min
Number of subjects: 1285

Group type: EXPERIMENTAL
Intervention: New algorithm for estimating Qb and K0A
Number of subjects: 1285

Group type: EXPERIMENTAL
Intervention: Multiple regression analysis
Number of subjects: 1285
Study: 11117451

Group type: EXPERIMENTAL
Intervention: Lead stimulus change (acoustic vs. visual)
Number of subjects: 96

Group type: COMPARATOR
Intervention: No change condition
Number of subjects: 96
Study: 9327699

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nicorandil
Number of subjects: 20
Study: 8404176

Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline 0.125 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline 1.5 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (PEP) 10 cm H2O
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (PEP) 15 cm H2O
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (PEP)
Number of subjects: 10
Study: 3492486

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (250 mg twice daily for ten days)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Co-trimoxazole (160 mg trimethoprim and 800 mg sulphamethoxazole twice daily for ten days)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 65

Group type: COMPARATOR
Intervention: Co-trimoxazole
Number of subjects: 65
Study: 3398018

Group type: EXPERIMENTAL
Intervention: Self-instruction videotape
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Viewing and critiquing a videotape of their interview
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both self-instruction videotape and critiquing a videotape of their interview
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no educational interventions)
Number of subjects: 60
Study: 31734992

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous portal vein punctures combined with bi-directional angiography
Number of subjects: 15

Group type: COMPARATOR
Intervention: Traditional methods for TIPS
Number of subjects: 15
Study: 28793880

Group type: EXPERIMENTAL
Intervention: Pentraxin-3 (PTX-3)
Number of subjects: 213
Study: 26093156

Group type: EXPERIMENTAL
Intervention: Multimodal imaging marker (randomized denoising autoencoder marker, rDAm)
Number of subjects: 0
Study: 23123868

Group type: EXPERIMENTAL
Intervention: Repetitive passive movement (RPM) intervention, 3 times a week for 8 weeks, using a continuous passive motion device at a velocity of 15°/s for 20 min
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 18
Study: 21540741

Group type: EXPERIMENTAL
Intervention: GW842166 800 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GW842166 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18510961

Group type: EXPERIMENTAL
Intervention: Flavanol-rich cocoa (321 mg flavanols per dose)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Nutrient-matched control (25 mg flavanols per dose)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Flavanol-rich cocoa (single acute dose)
Number of subjects: 41
Study: 16556691

Group type: EXPERIMENTAL
Intervention: Fluticasone
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 12777271

Group type: EXPERIMENTAL
Intervention: Long-acting risperidone 25 mg
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Long-acting risperidone 50 mg
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Long-acting risperidone 75 mg
Number of subjects: 554

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Long-acting risperidone (all doses)
Number of subjects: 554
Study: 10689248

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Patients with FMR
Number of subjects: 17
Study: 9315986

Group type: EXPERIMENTAL
Intervention: Trazodone 100 mg/day + Fluoxetine 20 mg/day
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: COMPARATOR
Intervention: Pindolol 7.5 mg/day
Number of subjects: 27
Study: 8447613

Group type: EXPERIMENTAL
Intervention: Subarachnoid morphine 0.25 mg with adrenaline 200 micrograms (group MA)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Subarachnoid morphine 0.25 mg without adrenaline (group M)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Normal saline (group C)
Number of subjects: 75
Study: 3948442

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30658914

Group type: EXPERIMENTAL
Intervention: ARD-3150 (3 mL liposome encapsulated ciprofloxacin 135 mg and 3 mL free ciprofloxacin 54 mg)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo (6 mL placebo: 3 mL dilute empty liposomes mixed with 3 mL of saline)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: ARD-3150
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study: 28393819

Group type: EXPERIMENTAL
Intervention: Cemented posts (dual: Ambar/Allcem)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Relined posts (dual: Ambar/Allcem)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Cemented posts (chemical: Fusion Duralink/Cement Post)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Relined posts (chemical: Fusion Duralink/Cement Post)
Number of subjects: 72
Study: 26241250

Group type: EXPERIMENTAL
Intervention: Intracesarean delivery
Number of subjects: 112

Group type: COMPARATOR
Intervention: Interval IUD placement
Number of subjects: 112
Study: 24215228

Group type: EXPERIMENTAL
Intervention: Patient navigation intervention (smoking cessation brochure, list of smoking cessation resources, and patient navigation)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (smoking cessation brochure and a list of smoking cessation resources)
Number of subjects: 47
Study: 21189431

Group type: EXPERIMENTAL
Intervention: Atorvastatin, 10 mg daily for 2 months
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Lovastatin, 40 mg daily for 2 months
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Simvastatin, 20 mg daily for 2 months
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Atorvastatin, Simvastatin, Lovastatin
Number of subjects: 95
Study: 18776057

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) and leucovorin (LV) plus bevacizumab (BV)
Number of subjects: 249

Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) and leucovorin (LV)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: irinotecan, 5-FU, and leucovorin (LV) plus bevacizumab (BV)
Number of subjects: 249

Group type: COMPARATOR
Intervention: irinotecan, 5-FU, and leucovorin (LV)
Number of subjects: 249
Study: 17161072

Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) intervention in 19 hospitals
Number of subjects: 6726

Group type: COMPARATOR
Intervention: Control group in 19 hospitals
Number of subjects: 6726
Study: 14961173

Group type: EXPERIMENTAL
Intervention: Once daily application of Dovobet (calcipotriol 50 micrograms/gram and betamethasone dipropionate 0.5 milligrams/gram)
Number of subjects: 5500

Group type: COMPARATOR
Intervention: Twice daily application of Dovobet
Number of subjects: 5500

Group type: COMPARATOR
Intervention: Individual components used alone (calcipotriol or betamethasone dipropionate)
Number of subjects: 5500
Study: 10660736

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU), 300 mg/day
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CPA), 150 mg/day
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: 5-FU + CPA
Number of subjects: 166

Group type: COMPARATOR
Intervention: Overall survival
Number of subjects: 166
Study: 9070555

Group type: EXPERIMENTAL
Intervention: Exercise training only
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Dietary modification only
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Exercise training plus dietary modification
Number of subjects: 55
Study: 8451405

Group type: EXPERIMENTAL
Intervention: Body temperature contrast medium (n = 117)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Room temperature contrast medium (n = 133)
Number of subjects: 250
Study: 3085464

Group type: EXPERIMENTAL
Intervention: Nifedipine (60 to 90 mg/day)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Propranolol (240 mg/day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 31569173

Group type: EXPERIMENTAL
Intervention: Multimodal exercise program plus neural gliding
Number of subjects: 26

Group type: COMPARATOR
Intervention: Multimodal exercise program only
Number of subjects: 26
Study: 30475961

Group type: EXPERIMENTAL
Intervention: High-fat diet with higher genetic risk score (GRS) for vitamin D
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: High-fat diet with lower genetic risk score (GRS) for vitamin D
Number of subjects: 424

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 424
Study: 29262474

Group type: EXPERIMENTAL
Intervention: Electrical velocimetry (EV)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional central venous pressure (CVP)
Number of subjects: 60
Study: 25783672

Group type: EXPERIMENTAL
Intervention: Concerted action to reduce cesarean section rates
Number of subjects: 0
Study: 23468176

Group type: EXPERIMENTAL
Intervention: Etanercept at 0.4 mg/kg per week for the first year, then 0.4 mg/kg per month for the second year
Number of subjects: 31
Study: 21112538

Group type: EXPERIMENTAL
Intervention: liposome‐encapsulated 2% ropivacaine gel (RL2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 20% benzocaine gel (B20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo gel (P)
Number of subjects: 40

Group type: COMPARATOR
Intervention: liposomal placebo gel (LP)
Number of subjects: 40
Study: 18480205

Group type: EXPERIMENTAL
Intervention: 20 microg of rFVIIa per kilogram
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: 80 microg of rFVIIa per kilogram
Number of subjects: 841

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: All groups (placebo, 20 microg rFVIIa, 80 microg rFVIIa)
Number of subjects: 841
Study: 16641282

Group type: EXPERIMENTAL
Intervention: Maraviroc (MVC)
Number of subjects: 64
Study: 14765752

Group type: EXPERIMENTAL
Intervention: Distance from the contact point to the bone crest of 5 mm or less
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Distance from the contact point to the bone crest of 6 mm
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Distance from the contact point to the bone crest of 7 mm or greater
Number of subjects: 45
Study: 11044164

Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional therapy (nil-by-mouth regimen)
Number of subjects: 27
Study: 8652355

Group type: EXPERIMENTAL
Intervention: MLD children
Number of subjects: 40

Group type: COMPARATOR
Intervention: Typical children
Number of subjects: 40
Study: 1859906

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-relapse tamoxifen therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CMF adjuvant therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2-year course of tamoxifen
Number of subjects: 0
Study: 6125172

Group type: EXPERIMENTAL
Intervention: Propranolol (3 x 40 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pindolol (3 x 5 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Both beta‐adrenoceptor blockers
Number of subjects: 10
Study: 31827767

Group type: EXPERIMENTAL
Intervention: Manipulative therapy
Number of subjects: 238

Group type: COMPARATOR
Intervention: Non-manipulative therapy
Number of subjects: 238
Study: 27657352

Group type: EXPERIMENTAL
Intervention: Progressively increasing task difficulty (PT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No progression (NPT)
Number of subjects: 0
Study: 26715818

Group type: EXPERIMENTAL
Intervention: ERAS program (n = 30)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional control group (n = 31)
Number of subjects: 61
Study: 23867982

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TMX) 20 mg orally for 3 months
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 20727096

Group type: EXPERIMENTAL
Intervention: Cryoablation (CRYO)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Radiofrequency ablation (RF)
Number of subjects: 20
Study: 18695943

Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 20479
Study: 16967285

Group type: EXPERIMENTAL
Intervention: Pelvic-floor exercises (24 training sessions over 3 months)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Biofeedback therapy (16 sessions over 2 months)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Pelvic-floor exercises and biofeedback therapy
Number of subjects: 56
Study: 15689088

Group type: EXPERIMENTAL
Intervention: DTPa HBV-IPV-Hib vaccine at 1 1/2, 3 and 5 months of age
Number of subjects: 150

Group type: COMPARATOR
Intervention: DTPa-IPV-Hib vaccine at 1 1/2, 3 and 5 months of age with separate HBV vaccine at 1 and 5 months of age
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: DTPa HBV-IPV-Hib vaccine
Number of subjects: 150
Study: 11694208

Group type: EXPERIMENTAL
Intervention: Bupropion SR, 150 mg/day
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 9450160

Group type: EXPERIMENTAL
Intervention: Pivagabine (450-900 mg/d by oral route)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (identical quantities to pivagabine)
Number of subjects: 90
Study: 8565166

Group type: EXPERIMENTAL
Intervention: Early ICD implantation
Number of subjects: 60

Group type: COMPARATOR
Intervention: EP-guided strategy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Antiarrhythmic drugs as sole therapy
Number of subjects: 60
Study: 2338696

Group type: EXPERIMENTAL
Intervention: High salt diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low salt diet
Number of subjects: 0
Study: 7397057

Group type: EXPERIMENTAL
Intervention: Brotizolam 0.2 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Brotizolam 0.4 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Brotizolam 0.6 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Brotizolam 0.2 mg (night)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Brotizolam 0.4 mg (night)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Brotizolam 0.6 mg (night)
Number of subjects: 12
Study: 31694094

Group type: EXPERIMENTAL
Intervention: tiotropium/olodaterol 5/5 μg
Number of subjects: 548

Group type: COMPARATOR
Intervention: tiotropium 5 μg
Number of subjects: 548

Group type: COMPARATOR
Intervention: olodaterol 5 μg
Number of subjects: 548
Study: 29021000

Group type: EXPERIMENTAL
Intervention: Irrigation fluid at body temperature (37 oC)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Irrigation fluid at room temperature
Number of subjects: 600
Study: 25390281

Group type: EXPERIMENTAL
Intervention: Separate nasal prongs (Salter)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Bifurcated nasal prongs (Hudson)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Multi-vented nasal cannula (Oridion)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Dual-vented nasal cannula (Medline)
Number of subjects: 45
Study: 25089344

Group type: EXPERIMENTAL
Intervention: Affective communication
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard communication
Number of subjects: 50
Study: 21703750

Group type: EXPERIMENTAL
Intervention: Post exercise changes of urinary leukotriene E4 (LTE4) concentration in children with EIA
Number of subjects: 25

Group type: COMPARATOR
Intervention: Post exercise changes of urinary leukotriene E4 (LTE4) concentration in healthy controls
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Changes of LTE4 concentration post ECT in children with EIA
Number of subjects: 25

Group type: COMPARATOR
Intervention: Changes of LTE4 concentration post ECT in healthy controls
Number of subjects: 25
Study: 20214067

Group type: EXPERIMENTAL
Intervention: Tranquilizing and allaying excitement needling method (acupuncture at Sishencong, Shenmen, and Sanyinjiao)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Eight confluence points selected needling method (acupuncture at Shenmai and Zhaohai)
Number of subjects: 60